CAR T-Cell Therapy | Clinical

Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma

June 30, 2022

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

Understanding CAR T-Cell Therapy Utilization Patterns in the Community Oncology Setting

June 08, 2022

In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.